Brief: Celldex Therapeutics Says Barzolvolimab Meets Primary Efficacy Endpoint In Phase 2 CSU Study
14/06/2026 15:26
BRIEF-Celldex Therapeutics Says Barzolvolimab Meets Primary Efficacy Endpoint In Phase 2 CSU Study June 14 (Reuters) - Celldex Therapeutics Inc CLDX.O:
CELLDEX PRESENTS LONG-TERM BARZOLVOLIMAB RESULTS DEMONSTRATING SUSTAINED OFF-TREATMENT IMPROVEMENT IN ANGIOEDEMA IN PATIENTS WITH CSU AT THE EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY ANNUAL MEETING
CELLDEX THERAPEUTICS - BARZOLVOLIMAB MEETS PRIMARY EFFICACY ENDPOINT IN PHASE 2 CSU STUDY
Source text: ID:nGNXc8lPHs
Further company coverage: CLDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celldex Therapeutics
See all newsUS RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Celldex shares slip as safety concerns cloud skin drug trial win (updated)
Celldex falls after two probable anaphylaxis cases in trials
Celldex's skin disease drug meets goals in two late-stage trials